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PURPOSE. We report on the in vivo testing of a novel noninvasively adjustable glaucoma
drainage device (AGDD), which features an adjustable outflow resistance, and assess the
safety and efficiency of this implant.
METHODS. Under general anesthesia, the AGDD was implanted on seven white New Zealand
rabbits for a duration of 4 months under a scleral flap in a way analogous to the Ex-PRESS
device and set in an operationally closed position. The IOP was measured on a regular basis
on the operated and control eyes using a rebound tonometer. Once a month the AGDD was
adjusted noninvasively from its fully closed to its fully open position and the resulting
pressure drop was measured. The contralateral eye was not operated and served as control.
After euthanization, the eyes were collected for histology evaluation.
RESULTS. The mean preoperative IOP was 11.1 6 2.4 mm Hg. The IOP was significantly lower
for the operated eye (6.8 6 2 mm Hg) compared to the nonoperated eye (13.1 6 1.6 mm Hg)
during the first 8 days after surgery. When opening the AGDD from its fully closed to fully
open position, the IOP dropped significantly from 11.2 6 2.9 to 4.8 6 0.9 mm Hg (P < 0.05).
CONCLUSIONS. Implanting the AGDD is a safe and uncomplicated surgical procedure. The
fluidic resistance was noninvasively adjustable during the postoperative period with the
AGDD between its fully closed and fully open positions.
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aqueous humor
Glaucoma is a leading cause of blindness affecting severalmillion patients worldwide.1,2 Decreasing the IOP is one
of the most important requirements to control the progression
of glaucoma efficiently.3 The number of valuable options in
glaucoma filtering surgery has increased over the last decade.4,5
Trabeculectomy and the use of implantable drainage devices or
stents are parts of the armamentarium available nowadays in
modern glaucoma filtering procedures. Glaucoma drainage
implants become increasingly popular because they may offer
better IOP control over time, reducing the number of
postoperative complications.6,7 Still, predicting postoperative
IOP and maintaining it at optimal levels remains a key problem.
For instance, the risk of early postoperative complications, such
as hypotony, always is present. Hypotony could entrain
complications requiring further surgeries.8,9 In that respect,
the possibility to control the fluidic resistance of an implanted
drainage device during the postoperative follow-up would have
been very helpful in maintaining IOP always at optimal levels,
thereby potentially avoiding a number of complications related
to poor pressure control.
Recently, a new experimental noninvasively adjustable
glaucoma drainage device (AGDD) has been developed.10 In
vitro results demonstrated that the fluidic resistance of the
device can be adjusted to consequently regulate the IOP. To
assess the safety and the efficiency of the novel device, we
report the first in vivo testing of this AGDD.
MATERIALS AND METHODS
The principle of the AGDD system was first described by
Stergiopulos,11 further developed and patented by Bigler12 and
Stergiopulos,11 and described in details by Villamarin et al.10
Briefly, the system comprises the AGDD implant and the
external measurement/adjustment device, hereafter called the
control unit (CU; Fig. 1). The AGDD contains a simple
mechanism, which allows for a selective compression of an
incorporated drainage tube, thereby adjusting its fluidic
resistance. This is achieved using the combination of an
eccentrically placed magnetic disk (that is placed on ball
bearings facilitating its rotation) and a ring compressing the
silicone tube; the angle of rotation, thus, determines the
amount of compression of the drainage tube, and, therefore, its
fluidic resistance. The magnetic disk is rotated using the CU,
which contains a magnet at one end and a compass on the
other end. When placed on top of the implanted AGDD, the
compass indicates the actual rotational position of the magnetic
disk. The magnet is used to rotate the magnetic disk, by
appropriately dragging the magnet along the periphery of the
implant in the clockwise or counterclockwise direction. The
reading (compass) and the adjustment (magnet) of the
rotational position of the implant are done noninvasively and
without even touching the eye (Fig. 1).
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In Vivo Experiment
The study was done on seven white New Zealand rabbits for
duration of 4 months. General anesthesia was performed using
a mixture of 3 mg/kg (body mass) xylazine and 35 mg/kg
ketamine intramuscular injection. Under general anesthesia,
the AGDD was implanted in a way analogous to the Ex-PRESS
device.13 In short, a scleral flap of 7 3 7 mm (width 3 long)
was dissected and the nozzle was inserted through a
paracentesis made by a 25-gauge needle in the anterior
chamber between the cornea and the anterior surface of the
iris taking care not to touch either of these structures (Fig. 2).
The AGDD was implanted in a functionally closed position and
left in that position during the initial postoperative period (1
month). The end portion of the tube was placed freely under
the conjunctiva and aqueous humor was drained in the
subconjunctival space.
During the first postoperative week, IOP was measured
daily on the operated and control eyes using a rebound
tonometer (iCARE Tonovet; iCare, Vanda, Finland). In the
following weeks, such measurement was performed once a
week. Results were reported and compared for statistics.
Before each measurement, rabbits were placed in a bunny
snuggle (Colonial Medical Supply, Nashua, NH, USA) and
relaxed for 5 minutes. All measurements were performed at the
end of the morning (10 AM to 12 noon).
Once a month, the AGDD was adjusted noninvasively with
the CU from its fully closed position to its fully open position
and the resulting pressure drop was measured. Hypotony was
defined as an IOP equal or lower than 6 mm Hg (IOP  6 mm
Hg). The contralateral eye was not operated and served as
control. At the end of the study, the animals were euthanized
and the eyes were enucleated to perform histology to assess
the biocompatibility of the AGDD.
All experiments conformed to the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research, and were
reviewed and approved by the institutional committee for
animal studies in Lausanne, Switzerland.
Histology
The enucleated eyes were formalin-fixed, macroscopically
processed, and dehydrated through graded alcohol followed
by paraffin inclusion. Sections (5 lm) were cut and stained
with hematoxylin-eosin and Prussian blue. The local inflam-
matory response was assessed using the following parameters:
(1) density of lymphocytic and plasmacytic infiltrate around
the AGDD device (X ¼ number of cells/5 high power field
[HPF], 3400, 1.8 mm2), (2) density of eosinophilic infiltrate
(number of cells/5 HPF), (3) intensity of granulomatous
inflammation, and (4) fibrosis and scarring. A cellular density
< 10 cells/5 HPF was graded as minimal, 10 > X < 50 cells /5
HPF as mild, and X > 50 cells/5 HPF as marked inflammation.
The intensity of granulomatous reaction was graded as minimal
with only few macrophages and giant cells, moderate with
more granuloma, and marked with sheets of macrophages and
giant cells. The fibrosis and scarring was graded as minimal if
the scarring maximal thickness was inferior to 25% of the
scleral thickness, mild <50%, and moderate >50%.
Statistics
The results were expressed as the mean and SD. The paired
Student’s t-test was used to assess significant differences and
effects of the AGDD on the results. P < 0.05 was considered
statistically significant.
RESULTS
The mean preoperative IOP was 11.1 6 2.4 mm Hg. The
evolution of IOP during the entire postoperative period for the
animals is shown in Figure 3. For the seven rabbits, hypotony
was present in the operated eyes during the first 3 days after
implantation (mean IOP was 6.0 6 1.4 mm Hg) and the
difference with the control (nonoperated) eyes was significant
FIGURE 1. Picture of the AGDD (A) and the CU (B) used for the
measurement and the adjustment of the outflow resistance.
FIGURE 2. Picture of a rabbit eye where the AGDD was placed under a
scleral flap with its nozzle inserted in the anterior chamber.
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(P < 0.05). Eight days after surgery, hypotony was no longer
present (mean IOP, 11.3 6 0.8 mm Hg), and the difference in
IOP between control and operated eyes was no longer
significant (P ¼ 0.12, Fig. 3). In all rabbits, the IOP dropped
significantly from 11.2 6 2.9 to 4.8 6 0.9 mm Hg (P < 0.05)
when the AGDD was opened from its fully closed (maximum
outflow resistance) to fully opened (minimum outflow
resistance) position (Fig. 4). The range of IOP means from
the functional closed position of the AGDD to the functional
open position corresponded to: closed position, minimum¼ 7
mm Hg, maximum¼ 17 mm Hg; and open position, minimum
¼ 4 mm Hg, maximum 7 mm Hg. The pressure drop was
significant for all rabbits (P < 0.05, Fig. 5).
Microscopic examination of tissues surrounding the AGDD
showed a cavity covered by a layer of flattened macrophages
surrounded by partially reorganized dense connective tissue. In
some areas, aggregates of lymphocytes as well as scarce
eosinophils could be identified. The chronic inflammatory
infiltrate was minimal to mild in most cases (Fig. 6). More
precisely, the lymphocytic and plasmocytic inflammatory
infiltrate was mild in all cases. The eosinophilic infiltrate was
minimal in two cases and mild in five cases. A granulomatous
foreign body type reaction was observed around the suture
material. The intensity of the granulomatous reaction was
minimal to mild in five cases and mild to moderate in two
cases. The scarring and fibrous reaction was mild to moderate
in all cases. Finally, there was no intraocular inflammation, no
alteration of the retinal architecture, and no atrophy of the
ganglion cells layers present in any case. The optic nerves were
unremarkable in all cases.
DISCUSSION
The advantage of the novel glaucoma drainage device resides in
the possibility to adjust, noninvasively, its fluidic resistance to
the aqueous humor drainage. In that prospect, the goal of this
study was to demonstrate the safety, efficacy, ease of use, and
biocompatibility of the AGDD in an animal model.
Although rabbits are standard animal models commonly
used in ophthalmology research,14 the size of the rabbit eye is
significantly smaller than in humans. However, the anatomical
structures are comparable, providing a useful surgical model
for ophthalmic investigations.15 The rabbits used in this study
did not suffer from glaucoma. It is rather difficult to induce
glaucoma on rabbit eyes and to maintain an elevated IOP over
time. Several techniques, such as injection of microbeads into
the anterior chamber16 or occlusion of episcleral vessels,17,18
can be effective, but do not work for long-term follow-ups. In
addition, these techniques were tried on rodents, such as
mice or rats, that have too small eyes for the implantation of
the AGDD. Therefore, the capability in reducing elevated IOP
to normal range (e.g. in patients suffering from glaucoma)
could not be tested in this study. However, the ability of the
AGDD to reduce pressure levels (from normal to low
pressures) has been demonstrated clearly. Because the
implant operates on altering the fluidic resistance, one could
imagine that in presence of glaucomatous eyes, the IOP could
be reduced to pressures down to physiological range. Results
showed that the implant has efficiently decreased the IOP
once it was in its functionally open position. These results
demonstrated that over time the AGDD can be adjusted
noninvasively and consequently the resistance to outflow can
be adjusted accordingly. When the implant was readjusted
from the fully open to its fully closed position, the following
day, the IOP resumed its initial level (Fig. 4). These
observations are very encouraging, demonstrating the ability
of the implant to change the outflow facility and to help
control the IOP at the level of the tube. However, the
relatively narrow IOP range with this normotensive rabbit
model makes the reading of the IOP drop more difficult when
the AGDD is set on partially opened positions. Further clinical
studies with glaucomatous eyes having greater IOP range
should confirm that partially opened positions would lead to a
controlled IOP drop.
The surgical method to implant the AGDD is analogous to
the Ex-PRESS tube, which is comparable to the trabeculectomy
technique.19 Nevertheless, some minor changes were neces-
sary to correctly implant the AGDD. For instance, the size of
the scleral flap was substantially larger (73 7 mm) to correctly
fit the size of the AGDD.
FIGURE 3. Plot of the mean IOP over time. Measurements were done every week with an iCARE TonoVet. Postoperatively the difference between
the operated and control eyes was significant from days 1 to 8 (*). Transient hypotony was present in the operated eyes during the first 3 days after
implantation.
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Results showed that after a week (8 days, Fig. 3) the
difference in IOP between control and operated eyes was no
longer significant. For the eyes implanted with the AGDD, the
IOP went back to preoperative level after only a few days
following surgery and the hypotony was minimized (<4 days).
This short recovery time after the filtering procedure results
from the fact that the AGDD was inserted in its functional
closed position, thus, limiting outflow to the leakages around
the nozzle and allowing the eye to resume the initial IOP level.
However, the resistance to outflow regained the preoperative
level as a result of the paracentesis better accommodating the
diameter of the nozzle to a watertight fit. In humans, this
process would certainly have a different time profile.
The use of this AGDD as a modular flow resistance is most
efficient in the early stages after implantation. Following the
surgical procedure the AGDD could be set into a functional
closed position to minimize hypotony. Once the clinically
relevant IOP is reached, the resistance to outflow could be
adjusted in the early postoperative phase up to 2 to 3 months
after surgery.
The 4-month follow-up may be too short to fully evaluate
the mid- to long-term safety and efficacy profile of this AGDD.
This is the main limitation of this study. Further clinical
evaluations are planned to address these issues. Furthermore,
such filtering surgery using glaucoma drainage devices might
suffer from postoperative scarring processes. This would likely
occur in a late postoperative stage and as such might impede
aqueous outflow around the device, despite a patent and
functional tube. To address this issue, alternative ducting
FIGURE 4. Plot of the mean IOP over time and the AGDD in its functionally closed position. Once a month, the AGDD was fully opened and the
resulting pressure was measured (red square symbol). The arrows help visualize the magnitude of the pressure drop when the device was adjusted
from its fully closed to its fully opened position.
FIGURE 5. Plot of the mean IOP drop for all rabbits. The pressure drop was significant between the fully opened position of the AGDD and the fully
closed position.
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routes to more posterior drainage area, such as the orbital
cone, might be envisioned.
Critical aspects, such as safety and efficiency of the AGDD,
were assessed in this first in vivo study. The rate of aqueous
humor outflow was easily adjustable during the entire
postoperative period based on the control of the outflow
resistance of the AGDD between the fully closed and fully open
positions. The surgical technique to implant the AGDD is
comparable to the Ex-PRESS procedure, demonstrating the
simplicity and relative ease of use of the implant. These first in
vivo results provided encouraging data on the safety and
performance of the device. A human clinical trial will follow to
demonstrate all aspects of safety, performance, and efficacy of
the AGDD in glaucoma patients. This will provide an effective
means of controlling IOP during the initial postoperative
period on a per patient basis, in the aim to possibly minimize
the risk of hypotony in the early postoperative stages.
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FIGURE 6. Histopathologic analysis demonstrated a cavity lined by
flattened cells surrounded by few lymphocytes. Circumscribed
postsurgical cicatricial remodeling can be observed inferior to the
cavity in the dense connective tissue of the sclera. Original
magnification:363, hematoxylin-eosin.
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